On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...
Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...
Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...
Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...
Halozyme is relatively low-beta and an ideal stock in the biotech sector for a covered call trade with good liquidity on ...
On Monday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $51.77 which represents a decrease of $-0.84 or -1.60% from the prior close of $52.61. The stock opened at $52.6 ...
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 821,620 shares ...
The Graham number is √(22.5 * 5 year average earnings per share * book value per share), which for Halozyme Therapeutics gives us a fair price of $5.43. In comparison, the stock’s market price is ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback